Aventis Must Divest Estorra Rights For FTC Green Light On Sanofi Merger
This article was originally published in The Pink Sheet Daily
Executive Summary
Aventis has 90 days to sell rights to the insomnia agent back to Sepracor or another buyer approved by the Federal Trade Commission. The agency says Estorra would overlap with Sanofi’s Ambien.
You may also be interested in...
Quintiles Restructures Early Development/Lab Services Division
The division has underperformed in 2004, although recent business win trends are “encouraging,” CFO Ratliff says. The contract research and sales organization believes that underlying demand for its services remains strong, particularly in the product development area.
Quintiles Restructures Early Development/Lab Services Division
The division has underperformed in 2004, although recent business win trends are “encouraging,” CFO Ratliff says. The contract research and sales organization believes that underlying demand for its services remains strong, particularly in the product development area.
Aventis’ Estorra Rights Acquired By Private Equity Firm For $115 Mil.
The company is divesting its rights in the insomnia drug as part of a Federal Trade Commission consent agreement clearing the Sanofi merger. Paul Royalty Fund II, an affiliate of Paul Capital Partners, will make fixed and milestone payments.